Oral smeglutide is approved to be marketed in China for the treatment of type 2 diabetes
阿豆学长长ov
发表于 2024-1-26 17:31:48
255
0
0
On January 26, the information released by the National Drug Administration (NMPA) showed that Smeaglutide Tablets under Novo Nordisk (China) Pharmaceutical Co., Ltd. was approved for listing to treat type 2 diabetes. This is the first domestically approved oral GLP-1 (glucagon like peptide-1) receptor agonist.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- The magic medicine for weight loss has become popular: Novo Nordisk shows the indication literature Lilly shows the association between diabetes and obesity
- Smeaglutide tablet for type 2 diabetes was approved for marketing in China
- Oral smeglutide is approved to be marketed in China for the treatment of type 2 diabetes
- The latest research: Wegovy is also effective for patients with diabetes and heart failure
- Abbott: Science and technology enable daily management of diabetes, stable and accurate, and protect blood sugar health
